Pharmaceutical companies are prime targets for cyberattacks due to their valuable intellectual property (IP) and the high costs of disruption. Akamai’s whitepaper emphasizes that attacks can cause financial and reputational damage, from stolen IP to delayed clinical trials and lost revenue. Since 2020, attackers have increasingly targeted vaccine-related IP, affecting companies of all sizes. The whitepaper underscores the critical need for robust cybersecurity strategies to protect the pharmaceutical value chain—from R&D and manufacturing to distribution and patient treatment—against relentless cyber threats.

Join for free to read